



Compassionate

Oncology Medical Group

Bob Leibowitz, M.D.

DIPLOMATE
AMERICAN BOARDS OF INTERNAL MEDICINE
AND SUBSPECIALTIES OF
MEDICAL ONCOLOGY AND HEMATOLOGY

CURRICULUM VITAE

Robert L. Leibowitz, M.D.

BUSINESS ADDRESS: 2080 Century Park East, Suite 1005, Los Angeles, CA 90067
TELEPHONE: 310) 229-3555
FAX: (310) 229-3554
WEBSITE: <http://www.compassionateoncology.org>
BORN: January 25, 1945
PLACE OF BIRTH: Chicago, Illinois
MARITAL STATUS: Divorced
CHILDREN:

| | |
|-------------------------------|------------|
| Ira Haskell | 02/25/1969 |
| Joshua Chad | 08/24/1971 |
| Kimberly Leah | 03/20/1973 |
| Grandson - Samuel Harris | 03/18/1997 |
| Grandson - Max Aaron | 04/20/1999 |
| Granddaughter - Rachel Alexa | 07/25/2001 |
| Granddaughter - Hannah Rose | 03/03/2003 |
| Granddaughter - Sarah Ashley | 09/23/2004 |
| Granddaughter - Dalia Abigail | 01/13/2005 |
| Granddaughter - Sophia Ruby | 06/22/2006 |
| Granddaughter - Ariela Faye | 04/17/2007 |
| Grandson - Ezra Jordan | 10/18/2007 |
| Granddaughter - Maya Hazel | 03/27/2009 |
| Grandson - Eli Noah | 06/26/2009 |

EDUCATION AND TRAINING

COLLEGE

| | |
|-------------------------|------------------------|
| University of Wisconsin | Jan. 1963 - June 1963 |
| San Jose State | Sept. 1963 - June 1965 |
| University of Illinois | Sept. 1965 - June 1966 |

Dr. Bob never graduated from college. He was accepted to Medical School after 3 years of college. He needs one more year of German in order to obtain his college degree. Fortunately he did graduate from the University of Illinois Medical School "with Honors."

MEDICAL SCHOOL

| | |
|-------------------------------------|------------------------|
| University of Illinois, Chicago, IL | Sept. 1966 - June 1970 |
|-------------------------------------|------------------------|

STRAIGHT MEDICAL INTERNSHIP AND TWO YEARS MEDICAL RESIDENCY

| | |
|--|-----------------------|
| Presbyterian - St. Luke's, Chicago, IL | July 1970 - July 1973 |
|--|-----------------------|

FELLOWSHIP

Fellowship in Hematology-Oncology
Beth Israel and Peter Bent Brigham
Hospitals, Boston, Massachusetts

July 1973 - June 1975

These 2 are of (then) 4 full service Harvard Medical School affiliated hospitals – the other two were Massachusetts General Hospital and the Harvard Service at the Boston City Hospital.

BOARD CERTIFICATION

| | |
|-------------------------------------|---------------|
| American Board of Internal Medicine | June 1973 |
| American Board of Hematology | October, 1976 |
| American Board of Oncology | October, 1977 |

FACULTY POSITIONS

| | |
|---|-------------|
| Hebrew Union College | 1985 - 1990 |
| Clinical Faculty, UCLA | 1978 - 1983 |
| Clinical Instructor in Medicine Harvard Medical School | 1973 - 1975 |
| Research Fellow in Medicine Harvard Medical School | 1973 - 1975 |

MEMBERSHIPS

California Medical Association
Los Angeles County Medical Association
American Medical Association
American Society of Clinical Oncology
American Society of Hematology
American Urological Association
European Society for Medical Oncology
European Association of Urology
ASTRO American Society for Therapeutic
Radiology and Oncology
National Biotherapy Study Group
Harvard Alumni Foundation

HONORS

Alpha Omega Alpha Honor Medical Society
(Elected to AOA while still in medical school)
Graduated "With Honors" from Medical School
(only approximately 12 out of a class of 210 students were so honored)
Honorary discharge from the Air Force
First House Staff representative for Committee for Administrative and House
Staff Activities, Rush Presbyterian St. Lukes Hospital

Dr. Bob was chosen to write and deliver the Medical School Student Speech at the Student Faculty Dinner (University of Illinois, Chicago, IL).

He wrote the first House Staff Contract for Rush Presbyterian Hospital and it was accepted and adopted by the administration (Chicago, IL, 1971).

HOSPITAL APPOINTMENTS

| | |
|--|-------------------------------|
| Sherman Oaks Community Hospital Sherman Oaks, CA | 1978 - present |
| Director of Biotherapy Unit | 1990 – 1995 |
| Director of Oncology Unit | 1984 – 1990 |
| Valley Presbyterian Hospital, Van Nuys, CA | 1993 – 2006; 3/2008 – present |
| Century City Doctors Hospital, Los Angeles, CA | 2005 – 2008 |
| Century City Hospital, Los Angeles, CA | 1997 - 2004 |
| Cedars-Sinai Medical Center, Los Angeles, CA | 1997 – 1999; 2001 - 2003 |
| Westlake/Thousand Oaks/Salick Cancer Center, Westlake Village, CA | 1995 – 1997 |
| Encino Hospital, Encino, CA | 1977 - 1995 |
| Co-Founder and Co-Director of Oncology HOPE Unit | 1977 - 1982 |
| Chief of Medicine | 1980 - 1981 |
| Van Nuys Community Hospital, Van Nuys, CA | 1977 - 1995 |
| Medical Center of North Hollywood | 1991 - 1993 |
| Director of Oncology Unit | 1991 - 1993 |
| St. Joseph's Medical Center, Burbank CA | 1977 - 1982 |
| Fresno Community Hospital, Fresno, CA | 1975 - 1977 |

COMMITTEE APPOINTMENTS

| | |
|---|-------------|
| Chairman Cancer Committees | |
| Encino Hospital | 1981 - 1982 |
| Medical Center of Tarzana | 1979 - 1982 |
| Chairman Pharmacy & Therapeutic Committee | |
| Medical Center of Tarzana | 1979 - 1982 |
| Chairman Library Committee | |
| Encino Hospital | 1978 - 1982 |
| Member Medicine Committee | |
| Sherman Oaks Community Hospital | 1983 - 1995 |
| Encino Hospital | |
| Member Institutional Review Board | 1987 - 1995 |
| Sherman Oaks Community Hospital | |
| Member Bioethics Committee | 1987 - 1995 |
| Sherman Oaks Community Hospital | |

PROFESSIONAL ACTIVITIES

| | |
|---|---|
| Engaged in private practice specializing in Medical Oncology and Hematology <i>(Since 1998, practice is essentially limited to Prostate Cancer)</i> | 1975 - present |
| Investigator, National Cancer Institute Group, Medications | 1975 - present |
| Member, Medical Advisory Board PAACT (Patient Advocates for Advanced Cancer Treatment) and Member PCOG (Prostate Cancer Oncology Group) | 1995 - present |
| Invited Consultant, "Optimal Management of the AIPC Patient" by Sanofi Aventis U.S., Inc., Coronado, California | To be Held: 8/28-8/29/2009 |
| Investigator, Zometa Study for Novartis Pharmaceuticals | ~2002 - 2005 |
| Visiting Professor, Invited Speaker Lectures Four Venues in Germany, Montabaur, Germany University of Munich | Sept. 2002 |
| Convention of German Prostate Cancer Support Groups, Hanover, Germany | |
| Prostate Cancer Symposium Helios Clinic, Berlin, Germany | |
| Investigator, cyproterone acetate for Berlex Labs | 1985 - 1995 |
| Instructor second year Rabbinic Students Hebrew Union College | 1985 - 1995 |
| Investigator, National Biotherapy Medical Group | 1988 - 1995 |
| Investigator, RU486 for metastatic breast cancer | 1993 - 1995 |
| Investigator, Casodex Study Group for Astra Zeneca Pharmaceuticals | ~1989 -1991 |
| Investigator, Zoladex Study Group for Zeneca, Pharmaceuticals | ~1986 -1990 |
| Investigator, National Prostate Cancer Study Group | 1975 - 1977 |
| Conceived, founded and was Medical Director of Oncology Unit Sherman Oaks Community Hospital Medical Center of North Hollywood Encino Hospital – HOPE Unit, first dedicated oncology unit in San Fernando Valley | 1985 - 1991 1991 - 1993 1977 - 1982 |
| Created, founded and moderated Cancer Grand Rounds Medical Center of Tarzana Encino Hospital | 1978-1982 1978-1982 |

PUBLICATIONS IN MEDICAL JOURNALS OR IN VARIOUS ASCO ABSTRACTS PROCEEDINGS

1. Leibowitz, R.L. et. al. Testosterone Replacement in Prostate Cancer Survivors with Hypogonadal Symptoms – **manuscript accepted for publication in the *British Journal of Urology International*.**
2. Leibowitz, R.L. et. al. Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade[®]: Preliminary Results in 110 Consecutive Patients. *The Oncologist*. 2001; 6: 177-182.
*Also published in the *PAACT Cancer Communications Newsletter*. April 2001; 17 (3).
3. Shaw, G., Leibowitz R., Tucker, S. Wilson P., Cuzick J, Prowse D., Goldenberg S.L., Spry N., Prapotnich D., Malone S., Forman J., Scholz, M.C., Strum, S., Small E.J., Zerbib, M., & Oliver R.T.D. Finasteride prolongs the off treatment period and improves survival when used as part of Triple Androgen Blockade[®] and for maintenance in intermittent hormone therapy for prostate cancer – manuscript submitted.
4. Shaw, G., Wilson P., Cuzick J, Prowse D., Goldenberg S.L., Spry N., Leibowitz R., Tucker, S. Prapotnich D., Malone S., Forman J., Scholz, M.C., Strum, S., Albrecht W., Small E.J., Zerbib, M., & Oliver R.T.D. International Study into the use of Intermittent Therapy in the Treatment of Carcinoma of the Prostate (ISICAP), a meta-analysis of 1653 patients – manuscript submitted.
5. Leibowitz, R.L. & Tucker S.J. PSA Response to Thalidomide in Patients with Advanced Prostate Cancer. *Oncology*. 2002; September; 16 (9), 1146, 1148. Letter to the Editor.
6. Leibowitz, R.L. & Tucker S.J. Primary Intermittent Chemo-Hormonal Therapy (CHT) for High Risk Locally Advanced (LAPC) or Metastatic Prostate Cancer (MPC): Preliminary Results and Quality of Life (QOL). *Proceedings of the American Society of Clinical Oncology*. 2005; 24 (4734)
7. Leibowitz, R.L. et. al. Primary Triple Androgen Blockade[®] (TAB) followed by finasteride maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL). Paper presented at: American Society of Clinical Oncology Prostate Cancer Symposium; 2005 (106)
8. Leibowitz, R.L. & Tucker S.J. Low and Intermediate Risk Early Prostate Cancer (PC) Managed with Triple Androgen Blockade[®] (TAB). *Proceedings of the American Society of Clinical Oncology*. 2003; 22 (1704).
9. Leibowitz, R.L. & Tucker S.J. Five-Year Follow-Up of Intermittent Triple Androgen Blockade[®] (TAB) for Clinically Localized Prostate Cancer (PC): Prognostic Features and Preliminary Patterns of Failure. *Proceedings of the American Society of Clinical Oncology*. 2002; 21(2481).
10. Leibowitz, R.L. & Tucker S.J. At What PSA Level Should Cycle Two of Hormone Blockade (HB) Commence in Men Who Refuse Local Treatment For Prostate Cancer (CaP) and Are Treated With Intermittent Androgen Blockade (AB)? *Proceedings of the American Society of Clinical Oncology*. 2002; 21 (2486).
11. Leibowitz, R.L. et. al. Intermittent Hormone Blockade for Localized Prostate Cancer. *Proceedings of the American Society of Clinical Oncology*. 2001; 20: 2372.

**PUBLICATIONS IN MEDICAL JOURNALS OR IN VARIOUS ASCO ABSTRACTS PROCEEDINGS
(CONTINUED)**

12. Scholz, M.C., Leibowitz, R. et al. Low-Dose Single-Agent Weekly Docetaxel (Taxotere) is Effective and Well Tolerated in Elderly Men with Prostate Cancer. *Proceedings of the American Society of Clinical Oncology*. 2001; 20 (2441).
13. Leibowitz, R.L. Hormone Blockade as the Sole Treatment of Clinical Stages T1-T3 Prostate Cancer: Experience in 100 Patients. *Proceedings of the American Society of Clinical Oncology*. 2000; 10 (1493).
*see attached abstract
14. Lynch, H.T., Leibowitz, R., Smyrk T., Fusaro, R.M., Lynch, J.F., Smith, A., Franklin, B., Stella, A., Liu, B. Colorectal Cancer and the Muir-Torre Syndrome in a Gypsy Family: A Review. *American Journal of Gastroenterology*. 1999; 94(3): 575-580.
15. Taylor, S.E., Lichtman, R.R., Wood, J.V., Bluming, A.Z., Dosik, G.M., Leibowitz, R.L.: Breast Self-Examination Among Diagnosed Breast Cancer Patients. *Cancer*. 1984; 54 (11): 2528 – 2532.
16. Lichtman, R.R., Taylor, S.E., Wood, J .V., Bluming, A.Z., Dosik, G.M., Leibowitz, R.L.: Relations With Children After Breast Cancer: The Mother Daughter Relationship At Risk. *Journal of Psychosocial Oncology*. 1985; 2 (3): 1-19.
17. Taylor, S.E., Lichtman, R.R., Wood, J.V., Bluming, A.Z., Dosik, G.M., Leibowitz, R.L.: Illness-Related Factors in Psychological Adjustments to Breast Cancer. *Cancer*. 1985; 55 (10): 2506 – 2513.
18. Bluming, A.Z., Ozohan, M.L., Marks, R., Leibowitz, R.L., Thompson, R.W., Drickman, M., Fingerhut, A.G., Schlesinger, M., Dosik, G.M. Lumpectomy (L), Radical Axillary Node Dissection (D), External Beam Radiotherapy (RTE), and Iridium Implant (I) As Treatment of Primary Breast Cancer - A Community Based Study. *Proceedings of the American Society of Clinical Oncology*. 1980; 21 (405).

OTHER PUBLICATIONS

- * Leibowitz, R.L. High Dose Testosterone Replacement Therapy (TRT) and Prostate Cancer (CaP) - Part 2. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. December 2006; 22 (4): 14-19.
 - * Leibowitz, R.L. High Dose Testosterone Replacement Therapy (TRT) and Prostate Cancer (CaP) - Part 1. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. September 2006; 22 (3): 13-18.
 - * Leibowitz, R.L. & Tucker S.J. Testosterone Levels and Prostate Cancer - The Higher, The Better? *PAACT, Inc.: Prostate Cancer Communication Newsletter*. March 2003; 19(1): 7-14.
1. Leibowitz, R.L. Dr. Bob's (Not so) Secret Recipe for Treating Metastatic, Advanced or Recurrent Prostate Cancer. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. June 2009; 25 (2): 6-15.
 2. Leibowitz, R.L. Leukine (GM-CSF) and Revlimid, the Second Generation Thalidomide Product. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. March 2008; 24 (1): 9-15.

OTHER PUBLICATIONS (continued)

3. Leibowitz, R.L. Potpourri of Prostate Pearls and Insights. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. December 2007; 23 (4): 1-6.
 4. Leibowitz, R.L. Does Anyone Know the Best Form of Hormone Blockade. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. June 2006: 22 (2); 16-20.
 5. Leibowitz, R.L.et. al. Statins. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. September 2005; 21(3): 1-2.
 6. Leibowitz, R.L. & Tucker S.J. The Mantra of Compassionate Oncology: "The Best Local Treatment is Systemic Treatment." *PAACT, Inc.: Prostate Cancer Communication Newsletter*. March 2005; 21(1): 7-11.
 7. Leibowitz, R.L. & Tucker S.J. Update on Triple Androgen Blockade[®] and Finasteride (Proscar[®]) Maintenance. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. September 2003; 19(3): 6-10.
 8. Leibowitz, R.L. & Tucker S.J. Cox-2 Inhibitors. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. December 2002; 18 (4).
 9. Leibowitz, R.L. & Tucker S.J. "PCAAC" Prostate Cancer Antiangiogenic Cocktail. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. April 2002; 18 (2).
 10. Leibowitz, R.L. & Tucker S.J. Dr. Bob and Dr. Steve's Recommended Vitamin List, Plus Complementary Therapies and Alternative Medicines List. *PAACT Cancer Communications Newsletter*. December 2001; 17(4).
 11. Leibowitz, R.L. & Tucker S.J. Treatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade[®]: Preliminary Results in 110 Consecutive Patients. *PAACT Cancer Communications Newsletter*. April 2001; 17 (2).
- *Also published in the *The Oncologist*. 2001; 6: 177-182.
12. Leibowitz, R.L. I am the only one you are afraid to believe. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. July 2000. 16 (3).
 13. Leibowitz, R.L. Thalidomide, The Reversal of the Benedict Arnold Reputation. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. January 2000; 16 (1).
 14. Leibowitz, R.L. Dawning of the Age of Angiogenesis. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. July 1999; 15 (3).
 15. Leibowitz, R.L. Hormone Refractory Prostate Cancer: Astonishing Results (?). *PAACT, Inc.: Prostate Cancer Communication Newsletter*. January 1999; 15 (1).
 16. Leibowitz, R.L. The Transitional Zone Era - Part II. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. July 1998; 14 (3).
 17. Leibowitz, R.L. The Transitional Zone Era - Part I. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. April 1998; 14 (2).
 18. Leibowitz, R.L. The Capitulation of Radiation Therapy has Begun. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. October 1997; 13 (4).

OTHER PUBLICATIONS (continued)

19. Leibowitz, R.L. The Future is Now. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. July 1997; 13 (3).
20. Leibowitz, R.L. You Can Live with Clinically Confined Prostate Cancer. *PAACT, Inc.: Prostate Cancer Communication Newsletter*. February 1996; 12 (1).

LECTURES & PUBLIC SPEAKING

1. The Wellness Community,
Westlake Village, CA 5/2009
“Dr. Bob's Three Pronged Approach for Treating High-Risk Disease and Associated PC Pearls of Wisdom”
2. Fred Hutchinson Cancer Research Center
/University of Washington, 11/2008
Seattle, WA
“**High dose Testosterone Replacement Therapy and Prostate Cancer**”
3. Us TOO International, Inc.
Fullerton, California (Prostate Forum of Fullerton) 3/2007, 3/2004
10/2002,8/2001
3/2000, 3/1999 1/1998
San Jose, California 5/2005, 7/2001
Chicago, Illinois 5/2003 11/2001
Las Vegas, Nevada 4/2001
Thousand Oaks, California 6/1998
4. International Study of Intermittent Therapy for Cancer of the Prostate (ISICAP)
Vancouver, B.C., Canada 3/2006
“Prolonging IAB Remissions: Anti-angiogenic Cocktail and High Dose Testosterone Replacement Therapy”
London, England 3/2005
“Use of Primary IHT for Localized Prostate Cancer”
5. Glendale Memorial Prostate Cancer Support Group 6/2005
6. Multidisciplinary Prostate Cancer Conference
“Triple Hormone Blockade® (THB) Update: the Demise of the Gold Standard; The Rise of the Platinum and Diamond Standard; Peer Recognition”
Orlando, Florida 2/2005
7. First International Conference on IAB 5/2005
London, England

LECTURES & PUBLIC SPEAKING (continued)

- | | |
|---|---|
| <p>8. The Sixth Annual Massachusetts Prostate Cancer Symposium <i>“Challenging Prostate Cancer Treatment Biases – Is Nothing Sacred?”</i></p> <p>Sponsored by the American Cancer Society, American Foundation of Urologic Disease, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital Cancer Center, Tufts-New England Medical Center, et. al.</p> <p>One of two Keynote Speakers, giving Keynote Address, speaking on the benefits of testosterone, as well as update on Triple Hormone Blockade[®].</p> | <p>5/2003</p> |
| <p>9. Prostate Cancer Research Institute, Kenneth Norris, Invited Speaker</p> | <p>10/2002</p> |
| <p>10. Continuing Medical Education Conference, Medical Staff Century City Hospital, Los Angeles, California <i>“Antiangiogenic Cocktail and Testosterone Replacement Therapy”</i></p> | <p>10/2002</p> |
| <p>11. Cedars-Sinai Medical Center, Staff Lecture Department of Hematology/Oncology</p> | <p>1/2002</p> |
| <p>12. Informed Prostate Cancer Support Group San Diego, California</p> | <p>2/2002 1/1999 7/1997</p> |
| <p>13. Prostate Cancer Support Group, Lecture Series, Speaker Marina del Rey, California Brotman Memorial Hospital., Culver City, California Fullerton, California</p> | <p>2/2000, 7/1998 11/1997, 2/1997 1996, 1995 1994 1996</p> |
| <p>14. Massachusetts Prostate Cancer Symposium, Invited Speaker Marlboro, Massachusetts</p> | <p>5/1999 5/1998</p> |

INFORMATIONALS

(all informationals are available to be downloaded at www.CompassionateOncology.org/publications.html)

- * TRT Case Reports: High-Dose Testosterone Replacement Therapy (TRT) and Prostate Cancer (CaP) (revised) 5/2009
(revised) 3/2007
11/2006
- * High-dose Testosterone Replacement Therapy And Prostate Cancer (revised) 11/2006
2/2006
- * High Dose Testosterone Replacement Therapy (revised) 6/2004
09/2003
- * Discussion of ASCO presentation "Phase I trial of exogenous testosterone (T) for the treatment of castrate metastatic prostate cancer (PC)" (Morris MJ et. al. (6/2004)) 5/2004
- * Testosterone Levels and Prostate Cancer – The Higher, The Better? (revised) 1/2003
05/2002
- 1. Shingles; Vaccine and Post Shingles Pain 04/2009
- 2. Dr. Bob's (not so) Secret Recipe for Treating Metastatic, Advanced or Recurrent Prostate Cancer 11/2008
- 3. Antiangiogenic Cocktail (AAC) 8/2008
- 4. Taxotere Plus Avastin: Antiangiogenic Proof of Principle 4/2008
- 5. Proscar Greetings on Father's Day and Immediate Versus Deferred Hormone Blockade (revised) 6/2008
(revised) 4/2004
6/1997
- 6. Triple Hormone Blockade® Update: The Demise of the (Fool's) Gold Standard; The Rise of the "Platinum and Diamond Standard"; Peer Recognition from the Multidisciplinary Prostate Cancer Conference, Orlando, Florida, February 2005, and the First International Conference on IAB, London, England, March 2005 (revised) 6/2008
2/2006
- 7. Soy and Prostate Cancer 10/2007
- 8. Interferon and Anti-angiogenesis 6/2007
- 9. The Risk of Thrombosis (Blood Clots) and the use of Thalidomide and/or Revlimid 2/2007
- 10. Celebrex, and Anti-Cancer Activity 2/2007
- 11. Statin Drugs and Advanced Risk of Prostate Cancer 1/2007
- 12. Celebrex, a Cox-2 Inhibitor: Off Label Use for Treating Prostate and other Cancers 12/2006

INFORMATIONALS (continued)

| | |
|--|---|
| 13. Aredia Monotherapy to Control Metastatic, Hormone Refractory Prostate Cancer for more than Six Years | 11/2006 |
| 14. <u>LEUKINE</u> (GM-CSF) and <u>REVLIMID</u> , the Second Generation <u>THALIDOMIDE</u> Product | (revised) 6/2006 2/2006 |
| 15. Hormone Blockade; Continuous, Intermittent, or ? | 3/2006 |
| 16. Bisphosphonates and Osteonecrosis of the Maxilla and/or Mandible (Jaw Bones) | 10/2005 |
| 17. Dr. Bob's Recommended Vitamin List | (revised) 10/2005 5/2005 |
| 18. Iron Supplementation in Cancer Patients Receiving Aranesp or Procrit | 4/2005 |
| 19. Emerging Concepts and Clinical Implications of State-of-the-Art Medical Information Through the Eyes of Compassionate Oncology (Medical Information) | 5/2005 |
| 20. Iron Supplementation in Cancer Patients Receiving Aranesp or Procrit | 4/2005 |
| 21. Low Molecular Weight Heparins | 4/2005 |
| 22. Celebrex | 12/2004 |
| 23. HORMONE REFRACTORY PROSTATE CANCER: Treatment with Low-Dose Weekly Taxotere/Emcyt/Carboplatinum Chemotherapy | (revised) 8/2004 (revised) 12/1998 8/1998 |
| 24. Choice of Antihypertensives | 7/2004 |
| 25. Dawning of the Age of Angiogenesis | (revised) 4/2004 12/1998 |
| 26. Hormone Refractory Prostate Cancer, "Astonishing Results (?)" | (revised) 4/2004 8/1998 |
| 27. The Facts Doc, Just the Facts | (revised) 4/2004 11/1997 |
| 28. Angiostatin and Why Local Therapy Fails to Cure So Many Men | (revised) 4/2004 10/1997 |
| 29. Prostate "Pearls" | (revised) 4/2004 9/1997 |
| 30. The Will Rogers Phenomenon | (revised) 4/2004 9/1997 |
| 31. The Capitulation of Radiation Therapy has Begun | (revised) 4/2004 9/1997 |

INFORMATIONALS (continued)

- | | |
|---|----------------------------|
| 32. The Emperor's New Clothes or "The Platinum and Diamond Standard" | (revised) 4/2004 8/1997 |
| 33. Intermittent Androgen Blockade | (revised) 4/2004 7/1997 |
| 34. Triple Hormone Blockade® Update | 3/2004 |
| 35. Cholesterol | 3/2004 |
| 36. Bisphosphonates and Avascular Bone Necrosis | 2/2004 |
| 37. Statins | 12/2003 |
| 38. Early Hormone Blockade Works Ridiculously Well | 10/2003 |
| 39. Lycopene | 9/2003 |
| 40. Hormone Blockade Versus Radical Local Therapies – and the Winner Is ... | 11/2002 |
| 41. COX-2 Inhibitors | (revised) 10/2002 2001 |
| 42. "PCAAC" - Prostate Cancer Antiangiogenic Cocktail | (revised) 9/2003 1/2002 |
| 43. Discussion of a December 2001 National Cancer Institute Article (Treatment Options) | 1/2002 |
| 44. Thalidomide | 2001 |
| 45. I Am the Only One You Are Afraid to Believe | 1/1999 |
| 46. Thalidomide, The Reversal of the Benedict Arnold Reputation | 12/1998 |
-

This abstract shows that in May, 2000, Dr. Bob, as sole author and investigator, had already reported his results on his first 100 consecutive patients using Triple Hormone Blockade® as sole treatment for treating prostate cancer.

®Triple Hormone Blockade is the registered trademark of Robert L. Leibowitz MD.



American Society of Clinical Oncology

www.asco.org

Hormone Blockade as the Sole Treatment of Clinical Stages T1-T3 Prostate Cancer: Experience in 100 Patients.

Sub-category:
Genitourinary Cancer

Category:
Genitourinary Cancer

Meeting:
2000 ASCO Annual Meeting

Abstract No:
1493

Citation:
Proc Am Soc Clin Oncol 19: 2000 (abstr 1493)

Author(s):
Robert Leibowitz

Abstract:

The effect of treatment of clinical T1-T3 prostate cancer with a triple hormone blockade regimen was retrospectively evaluated. The study population consisted of 100 men consecutively presenting to a community based solo oncology practice with clinically localized or locally advanced prostate cancer. All patients had biopsy proof of prostate cancer. Gleason scores ranged from 4 to 10 (mean 6.55). Baseline PSA levels ranged from 0.39 ng/mL to 100 ng/mL (mean 13.23 ng/mL). Treatment consisted of a regimen of LHRH agonist (either leuprolide acetate or goserelin acetate) plus antiandrogen (either flutamide 750 mg daily or bicalutamide 150 mg daily) plus finasteride 5 mg daily for a mean duration for 13 months. This was followed by maintenance treatment with finasteride 5 mg daily. No patient has received any form of local therapy. Effectiveness of the regimen was judged on the basis of control of PSA levels and prostate-cancer cause-specific survival. During triple hormone blockade, PSA levels declined to unmeasurable levels (less than or equal to] 0.1 ng/mL) in each patient (mean time to unmeasurable levels = 4 months). After completing the 3-drug regimen (although all are taking maintenance finasteride 5 mg daily), these 100 patients have been followed for an additional mean of 20 months. 60 patients have been off their LHRH agonist and antiandrogen for at least 12 months (mean 30 months). In all but 1 of these 60 patients, PSA levels initially rose but then reached a stable plateau and are no longer rising. The longest follow-up on finasteride alone is 75 months. Most recent mean PSA level for these 60 patients is 1.42 ng/mL. None of the 100 patients has required a second cycle of androgen blockade. Cause-specific survival is 100%. Hormone blockade with the 3-drug regimen followed by finasteride maintenance appears to be a promising alternative for the management of patients with clinically localized or locally advanced prostate cancer.